Published June 11, 2020 | Version v1
Patent Open

CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2

  • 1. University of Chicago
  • 2. Baylor College of Medicine

Contributors

Description

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Files

US_2020_0181227_A1.pdf

Files (6.7 MB)

Name Size Download all
md5:68da67bf308026c066ecdb638a180d4a
6.7 MB Preview Download

Additional details

Identifiers

Patent number
US 2020/0181227 A1
Patent application number
201916675861
Other
oai:uchicago.tind.io:9739

Dates

Patent filed
2019-11-06

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine, Neurological Surgery